XTNT logo

XTANT MEDICAL HOLDINGS INC

XTNTNYSE AMERICAN
πŸ† #4438 by market capUS Equity
$0.36β–² $0.00 (+1.26%)
After hours Β· at close
πŸ””
Track XTNT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.3%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$51M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+14.2%
Healthy
πŸ“ŠGross Margin
59.4%
Healthy
πŸ’΅FCF Margin
-0.6%
Thin
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
76
Good
No chart data available for XTNT.

Trading Snapshot

Day Range
$0.36 – $0.37
52-Week Range
$0.27 – $0.95
Volume
$3.36B
Avg Volume
$2.64B
Shares Outstanding
140.3M
Next Earnings
Dec 4, 2026

Fundamentals Snapshot

Annual Revenue
$110M
Last Q Revenue
$30M
P/E Ratio
-4.6
P/S Ratio
0.5x
EPS (TTM)
$-0.08
Dividend Yield
0.00%
Dilution (1yr)
+8.3%

Why Investors Own XTNT

  • βœ“High-growth profile β€” revenue up +38.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 4% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

XTNT logo

XTANT MEDICAL HOLDINGS INC

XTNT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$134Mβ–² +14.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
62.9%β–² +8.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$7Mβ–Ό βˆ’160.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$10Mβ–Ό βˆ’163.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
150.5Mβ–² +8.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$12Mβ–² +$17M YoY
StockOtter Β· stockotter.space

About XTANT MEDICAL HOLDINGS INC

Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$0.45
β–² +25.6% Upside
High Target$0.54
Low Target$0.41
Based on 13 analysts

Latest News & Updates